Stay updated on RX-5902 in Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the RX-5902 in Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the RX-5902 in Triple Negative Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check11 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check18 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content or functionality of the page.SummaryDifference0.1%
- Check61 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed information about a Phase 2 study of RX-5902 for treating triple negative breast cancer, and the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference27%
- Check68 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to RX-5902 in Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RX-5902 in Triple Negative Breast Cancer Clinical Trial page.